This article was commissioned by Bayer Australia Limited. The second-generation androgen-receptor inhibitors (ARi’s) have shown metastases-free survival (MFS) and overall survival (OS) benefits in patients with non-metastatic castrate-resistant prostate cancer (nmCRPC),1-6 providing treatment options beyond continued androgen deprivation therapy (ADT). In a Bayer webinar chaired by Doctor Laurence Krieger, lead clinician and principal investigator for ...
How second-generation androgen-receptor inhibitors are changing the management of non-metastatic castration-resistant prostate cancer
19 Jan 2021
Sponsored by Bayer Australia Limited